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1. Introduction 
Living cells require energy to perform work, to maintain their organized structures, to 
synthesize cellular components, to generate electric currents and many other processes. 
Energy metabolism is a highly coordinated cellular activity in which enzymes are organized 
into discrete metabolic pathways that cooperate in degrading energy-rich nutrients from the 
environment. Glucose is the principal metabolic substrate for living cells including brain 
cells. It is rich in potential energy and is also a versatile precursor, giving rise to metabolic 
intermediaries for biosynthetic reactions. Glycogen is a polymer of glucose and is the form 
in which glucose is stored. The mammalian brain contains glycogen, which is located 
predominantly in astrocytes (Brown & Ransom, 2007). In particular situations, substrates 
other than glucose can be utilized by the brain. -hydroxybutyrate, acetoacetate and acetone 
are ketone bodies produced in the liver from Acetyl-CoA. Ketone bodies are an important 
source of brain energy in breast-fed neonates and during starvation when carbohydrates are 
scarce. However, it has been proposed that part of brain energy comes from the conversion 
of glucose to lactate at one location (within one cell) and part comes from the oxidation of 
lactate to pyruvate at another location (within the same cell or in a different cell).  
The brain makes up 2% of a person's weight. Despite this, even at rest, the brain consumes 
25% of the body's energy. Most of the energy consumed in the brain is attributable to 
restoration of the membrane gradient following neuronal depolarization. Neurotransmitter 
recycling, intracellular signaling and dendritic and axonal transport also require energy 
(Attwell & Laughlin, 2001). Even though neurons are responsible for massive energy 
consumption, the brain is made up of many cells, including neurons, glial and ependymal 
cells. Every brain cell has a specific function and thus every brain cell has different 
metabolic needs. Many of these specific functions are concerned with maintainance of 
neuronal transmission. For example, astrocytes play a central role in supporting neurons 
metabolically by producing lactate, through glycolysis and activation of glycogen 
catabolism (Brown & Ransom, 2007). Another critical factor for maintenance of neuronal 
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transmission is an adequate supply of nutrients and oxygen from blood. Neurotransmitters 
stimulate neurovascular messenger production in astrocytes and neurons. These molecules 
induce the local constriction and dilation of smooth muscle around the neighboring 
arterioles (Attwell et al., 2010). 
There have been several reports of metabolic impairment in a variety of neurodegenerative 
disorders such as Alzheimer's disease, Huntington's disease, amyotrophic lateral sclerosis 
and Parkinson's disease, among others (Mosconi et al., 2005, Leenders et al., 1986, Kuwert et 
al., 1993, Hattingen et al., 2009). Because brain is an expensive organ in energetic terms, 
disruptions in energy production may affect neuronal transmission and thus, neuronal 
survival. Moreover, deregulation of energy metabolism could be implicated in an increased 
production of oxidative species. Indeed, oxidative damage has been proposed in such 
disorders (Mazziotta et al., 1987, Navarro et al., 2009).  
2. Metabolic sources and principal metabolic pathways for brain energy 
metabolism 
There are two barriers protecting the brain from toxic metabolites: the blood-brain barrier 
and the blood-CSF barrier formed by epithelial cells of the choroid plexus. These barriers 
protect the brain from possible changes in the concentration of blood metabolites. In the 
same way, they work as selective filters to allow for controlled delivery of metabolic 
substrates into the brain. These metabolic substrates are mainly glucose, ketone bodies and 
some metabolic intermediaries such as lactate and pyruvate. 
2.1 Use of glucose in brain  
Glucose is an essential energy source for the adult human brain. According to in vivo studies 
using labeled 2-deoxyglucose or 2-fluorodeoxyglucose there is a correlation between brain 
function and brain metabolism (Sokoloff et al., 1977). Glucose is rich in potential energy and 
thus, it is a good metabolic fuel. In any tissue glucose can follow several metabolic pathways. 
In brain, glucose is almost entirely oxidized through sequential glycolysis and the tricarboxylic 
cycle (TCA) associated with oxidative phosphorylation. Glucose can also be stored as the 
polysaccharide, glycogen. Glucose is not only an excellent energetic fuel, it is also a remarkably 
versatile precursor supplying metabolic intermediaries for biosynthetic reactions. In brain 
most of these intermediaries serve to synthesize neurotransmitters and gliotransmitters, as 
well as other molecules of biological significance. Glucose oxidation via glycolysis provides 
metabolic intermediaries besides producing ATP. Glucose can be oxidized through an 
alternative pathway: the pentose phosphate pathway (PPP). Glucose oxidation through PPP 
provides 5-carbon monosaccharides for nucleic acid synthesis and NADPH for reductive 
biosynthetic processes and for mantainance of the redox balance in the cell. 
2.1.1 Glycolysis 
In glycolysis, a molecule of glucose is oxidized to two molecules of pyruvate. This oxidation 
occurs through ten enzyme-catalyzed reactions (Figure 1). The first step in glycolysis is 
phosphorylation of glucose at C-6, by hexokinase, to yield glucose-6-phosphate. Most of the 
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glucose-6-phosphate is degraded to pyruvate. But glucose-6-phosphate can be used to 
generate glucose-1-phosphate, which in turn is used to synthesize glycogen (see below) or to 
generate NADPH and ribose-5-phosphate through PPP (see below). Myo-inositol is also 
synthesized from glucose-6-phosphate and serves as a precursor for phosphatidylinositide 
signaling molecules. The first step in glycolysis and the next nine enzymatic reactions occur 
in all brain cells (Lowry & Passonneau, 1964). 
 
Fig. 1. Glycolysis. The first step in glycolysis is phosphorylation of glucose to glucose-6-
phosphate by hexokinase, an enzyme inhibited by the same glucose-6-phosphate. Glucose 
must be phosphorylated to glucose-6-phosphate for it to enter glycolysis. The most 
important step in the control of glycolytic flux is a reaction catalyzed by 
phosphofructokinase (PFK). PFK is inhibited by compounds that accumulate when energy 
status is high (ATP, citrate) and it is activated by products of functional metabolic activity 
(AMP, ADP). PFK1 in neurons is not activated by fructose 2,6-bisphosphate (Fructose-2,6-P2) 
because the enzyme that catalyzes F2,6BP production is constantly degraded. 
Major sites for the control of glycolytic flux are hexokinase (EC 2.7.1.1), 
phosphofructokinase 1 (PFK1, EC 2.7.1.11) and pyruvate kinase (EC 2.7.1.40; Lowry & 
Passoneau, 1964). Hexokinase catalyzes the transfer of a phosphate group from one 
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molecule of ATP to glucose (Figure 1). Type-I hexokinase is the predominant isoenzyme in 
brain (Wilson, 1995). This reaction is irreversible under intracellular conditions. Type-I 
hexokinase is normally saturated with substrate and strongly inhibited by its product, 
glucose-6-phosphate (Wilson, 2003). Type-I hexokinase binds to the outer mitochondrial 
membrane via a hydrophobic N-terminal sequence (Wilson, 1997). Type-I hexokinase 
interacts with porin (also named voltage-dependent anion channel) which is a membrane 
protein located at the outer mitochondrial membrane. When type-I hexokinase binds to 
mitochondria, the Ki for glucose-6-phosphate is increased and the Km for ATP is reduced, 
suggesting that the bound form is more active (Wilson, 2003). This association occurs 
alongside changes in the cellular metabolic state. It has also been proposed that type-I 
hexokinase can bind to microtubules in order to increase their activity. Indeed, under 
mitogenic stimulus, mitochondria and type-I hexokinase colocalization decreases, while 
tubulin and type-I hexokinase colocalization increases in glial cells (Sanchez-Alvarez et al., 
2004). These changes in localization are accompanied by an increase in glucose transporters 
(GLUTs) and hexokinase expression (Sanchez-Alvarez et al., 2004). Therefore, hexokinase 
and GLUTs should be key factors in the regulation of glycolytic flux capacity. 
All three isotypes of PFK1 (muscle [M], liver [L] and brain [B]) have been observed by 
immunohistochemical analysis in neurons and astrocytes. The three isoenzymes differ in their 
allosteric properties and their distribution in different brain cells. These differences might be 
important for regulation of brain glycolysis in the different cellular compartments. Regulation 
of PFK activity is a major control point for glycolysis (Passoneau & Lowry, 1964). PFK1 is 
inhibited by compounds that accumulate when energy status is high (ATP, citrate) and is 
activated by products of functional metabolic activity (AMP, ADP). The powerful allosteric 
activator of PFK1 is fructose 2,6-bisphosphate, which is produced by the enzymatic reaction 
catalyzed by phosphofructokinase 2 (PFK2 or PFKB, EC 2.7.1.105). PFKB3 is the main isoform 
expressed in brain. However, PFKB3 has been described as being constantly degraded via the 
E3 ubiquitin ligase anaphase-promoting complex/cyclosome (APC/C)-Cdh1 (Herrero-
Mendez et al., 2009). Therefore, glycolysis in neurons is not activated. Indeed, when 
mitochondrial respiration is inhibited, astrocytes upregulate their glycolytic rates through 
fructose 2,6-bisphosphate production, while neurons die quickly. Thus glucose must be 
oxidized through other metabolic pathways, such as PPP, in neurons (see below). 
Pyruvate kinase is expressed in neurons and astrocytes. But apparently, in brain, the 
reaction catalyzed by pyruvate kinase does not appear to be a major control point in 
glycolysis (Lowry & Passoneau, 1964). 
2.1.2 Glycogen metabolism 
Glucose can be stored in the form of glycogen in brain. Glycogen is synthesized from 
glucose-6-phosphate via glucose-1-phosphate and UDPglucose. Glycogen stores may only 
sustain brain metabolic turnover for a few minutes at most. Glycogen metabolism is 
regulated by two enzyme reactions, catalyzed by glycogen synthase and glycogen 
phosphorylase (Figure 2). Most, if not all, glycogen is localized in astrocytes (Vilchez et al., 
2007). However, neuronal cells express enzymatic machinery for glycogen synthesis. 
Glycogen synthase is expressed in cultured neurons in a highly phosphorylated (inactive) 
state (Vilchez et al., 2007).  Glycogen synthase phosphorylation is achieved by glycogen 
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synthase kinase 3 (EC 2.7.11.26). The abnormal activation of glycogen synthase is 
responsible for abnormal glycogen deposits in neurons, a feature observed in Lafora disease. 
Lafora disease is an autosomal recessive form of epilepsy which has been associated with 
mutations in malin and laforin genes. The malin-laforin complex induces the degradation of 
both PTG (regulatory subunit of protein phosphatase 1 that activates glycogen synthase) by 
dephosphorylation, and glycogen synthase. Interaction of malin and laforin is a regulated 
process that is modulated by the AMP-activated protein kinase (Solaz-Fuster et al., 2008). 
 
Fig. 2. Glycogen metabolism. Glycogen is synthesized in astrocytes by glycogen synthase 
(GS). Glycogenolysis is mediated by glycogen phosphorylase (GP). Both GS and GP are 
regulated in opposite directions by phosphorylation. GS is activated by protein 
phosphatase-1 and inhibited by GS kinase-3 (GSK-3). Both GS and protein phosphatase-1 
interact with glycogen via protein targeting to glycogen (PTG). In neurons, GS is present in a 
highly phosphorylated, inactive state and, together with PTG, is targeted for proteasome-
dependent degradation by the laforin-malin complex. Glycogenolysis in astrocytes depends 
on GP, which is activated by phosphorylation by several kinases, including the cyclic 
adenosine monophosphate (cAMP)-activated protein kinase A (PKA) in response to several 
neurochemical signals. Glycogenolysis in astrocytes leads to the production of lactate, which 
serves as an energy substrate for oxidative metabolism in the active neurons. 
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On the other hand, astrocytic glycogen is good for the brain. During synaptic activity, 
breakdown of astrocytic glycogen is stimulated by neurotransmitters such as glutamate and 
norepinephrine (Walls et al., 2008). Adrenergic agents cause protein kinase A (PKA) 
activation in astrocytes through metabotropic receptor binding. Glycogenolysis in astrocytes 
depends on glycogen phosphorylase, which is activated by phosphorylation of several 
kinases, including PKA (Benarroch, 2010). Glycogenolysis produces glucose-6-phosphate. It 
has been proposed that glucose-6-phosphate is used to produce metabolic substrates such as 
lactate, which can be exported from astrocytes to neuronal cells (Benarroch, 2010; Walls et 
al., 2008). It has also been proposed that glucose-6-phosphate from glycogen in astrocytes 
inhibits glycolysis (by hexokinase inhibition) and thus, glucose consumption is favored by 
neurons (DiNuzzo et al., 2011). In any case, glycogen is important for brain. Indeed 
glycogen metabolism in astrocytes only occurs in mature astrocytic cells. 
2.1.3 Pentose phosphate pathway 
The pentose phosphate pathway (PPP) generates NADPH and 5-carbon carbohydrates. PPP 
has two distinct phases (Figure 3). The first is the oxidative phase, in which NADPH is 
generated, and in the second phase, non-oxidative synthesis of 5-carbon carbohydrates 
occurs. Even if this pathway involves oxidation of glucose, its primary role is anabolic rather 
than catabolic. Glucose-6-phosphate dehydrogenase is the regulatory enzyme in PPP. It is 
regulated by the NADPH:NADP+ ratio and is allosterically stimulated by nicotinamide 
adenine dinucleotide phosphate (NADP+). The ratio of NADPH:NADP+ is normally high. 
Thus, this makes the cytosol a highly-reducing environment. 
NADP+ is a coenzyme used in anabolic reactions, such as lipid and nucleic acid synthesis, 
which require NADPH as a reducing agent. Therefore, the PPP has a more prominent 
function in developing brain compared to adult brain due to lipogenesis and myelin 
formation during development. Astrocytes have a glucose-6-phosphate dehydrogenase Ki 
10-times lower than glioma cells because PPP is an indicator of cellular biosynthesis, while 
glycolysis indicates cellular proliferation. However, adult brain slices from several age 
groups have shown similar PPP capacities. Thus, adult brain has a high PPP capacity. 
NADPH could be used for neurotransmitter and gliotransmitter turnover and to metabolize 
aldehydes and peroxides produced by monoamine oxidase, among other enzymes. In this 
way, NADPH is used to regenerate glutathione (GSH) from glutathione disulfide, which is a 
product of peroxide scavenging (Baquer et al., 1988).  
As was mentioned previously, neurons are unable to increase glycolysis due to the lack of 
PFKB3. PFKB3 is constantly degraded in neuronal cells and thus glucose should be directed 
mainly to the PPP to generate NADPH and regenerate GSH (Bolaños et al., 2010). Recently, 
it has been demonstrated that glucose metabolism and glycogen utilization is impaired in 
astrocytes with a chronic GSH deficit (Lavoie et al., 2011). So, PPP activity is important in 
other brain cells besides neurons. 
2.1.4 Tricarboxylic acid cycle and oxidative phosphorylation 
The tricarboxylic acid (TCA) cycle, also called the citric acid cycle or Krebs cycle, includes eight 
enzyme-catalysed chemical reactions, which are of central importance in all living cells. The 
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purpose of the TCA is the complete oxidation of acetyl carbons from acetyl coenzyme A 
(Acetyl-CoA) with the subsequent formation of NADH and FADH2 (Figure 4). The TCA cycle 
is closely linked to oxidative phosphorylation. In oxidative phosphorylation NADH and 
FADH2 are reoxidized. NADH and FADH2 electrons are transferred from electron 
 
Fig. 3. The pentose phosphate pathway and glutathione. In the oxidative branch of the 
pentose phosphate pathway, two NADPH are generated per glucose-6-phosphate. The only 
limiting reaction of the pathway is catalyzed by glucose-6-phosphate dehydrogenase 
(G6PDH), which is allosterically activated by NADP+. G6PDH catalyzes glucose-6-
phosphate oxidation and the production of the first NADPH. This NADPH is oxidized and 
thus glutathione is reduced. The second NADPH is generated through the oxidative 
decarboxylation of 6-phosphogluconate, a reaction catalyzed by glucose-6-
phosphogluconate dehydrogenase. The nonoxidative branch of the pentose phosphate 
pathway provides a reversible link with glycolysis by regenerating the two glycolytic 
intermediates glyceraldehyde-3-phosphate and fructose-6-phosphate.  
donors to consecutive electron acceptors, in which the last electron acceptor is oxygen 
(oxygen is reduced to H2O, Figure 4). The energy released by electrons flowing through this 
electron transport chain is used to transport protons across the inner mitochondrial 
membrane, generating a potential energy (as an electrochemical gradient). This energy is 
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used to synthesize ATP in a enzyme reaction catalyzed by a large enzyme called ATP 
synthase.  
 
Fig. 4. The tricarboxylic acid cycle (TCA) and oxidative phosphorylation. Pyruvate entry 
into the cycle is controlled by pyruvate dehydrogenase activity that is inhibited by ATP and 
NADH. Two other regulatory steps in the cycle are controlled by isocitrate and ┙-
ketoglutarate dehydrogenase, whose activity is controlled by the levels of high-energy 
phosphates. All dehydrogenases are stimulated by Ca2+. NADH and FADH2 produced in 
TCA are reoxidized by the donation of their electron to the electron transport chain, the final 
goal of which is reduction of oxygen to water. Electron flux is responsible for the necessary 
energy to drive ATP synthesis. 
2.1.4.1 Formation of Acetyl-CoA 
Acetyl-CoA is produced mainly from pyruvate, the product of glycolysis. Pyruvate enters 
the mitochondrion and it is oxidized via an enzyme reaction catalyzed by the pyruvate 
dehydrogenase complex. This is composed of three different enzymes that catalyse seven 
reactions in order to oxidize pyruvate to Acetyl-CoA. Pyruvate dehydrogenase complex Km 
for Acetyl-CoA is approximately 0.05 mM. which is similar to pyruvate concentrations in 
brain. The enzyme complex also requires a variety of substrates and cofactors: pyruvate, 
NAD+, thiamine pyrophosphate, FAD, lipoic acid and coenzyme A. Activity of pyruvate 
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dehydrogenase complex is regulated by phosphorylation state and Ca2+ concentration among 
other factors (Huang et al., 1998). Pyruvate dehydrogenase complex immunoreactivity has 
been observed in neuronal cells (Calingasan et al., 1994). A low pyruvate dehydrogenase 
complex enzyme activity and immunoreactivity has been described in neurons following 
ischemia and reperfusion. This could explain the reduced cerebral glucose and oxygen 
consumption that occurs after cerebral ischemia (Martin et al., 2005).  
Although brain Acetyl-CoA is mainly derived from pyruvate, it can also be synthesized 
form fatty acids, ketone bodies (see below), monocarboxylate acids, such as lactate (see 
below) and acetate. Fatty acids are mainly oxidized inside the mitochondria through -
oxidation to produce Acetyl-CoA, NADH and FADH2.  
2.2 Use of lactate and ketone bodies 
The transport of lactate and ketone bodies is accomplished by the monocarboxylate 
transporters (MCTs). Although BBB cells express MCT1, monocarboxylates cross the BBB 
with poor efficiency under physiological conditions. Only under extreme conditions, like 
starvation or prolonged exercise, could these compounds be important exogenous sources of 
metabolic fuel for the brain (Quistorff et al. 2008).  
2.2.1 Lactate formation and lactate oxidation 
Normally, when the glycolysis rate exceeds the rate of triose entry into the TCA cycle, 
pyruvate can be reduced to lactate by lactate dehydrogenase (LDH, EC 1.1.1.27) which 
catalyzes a reversible reaction (Figure 1). Lactate must be released because local lactate 
accumulation would be an opposing driving force that would influence many reversible 
NAD+/NADH-coupled redox reactions. 
Extracellular lactate is transported into the cell and is oxidized to pyruvate because LDH 
catalyzes the reversible interconversion between pyruvate and lactate. Two distinct subunits 
combine to form the five tetrameric isoenzymes of LDH. The LDH-5 subunit (muscle type, 
also termed the A or M subunit) has a higher maximal velocity (Vmax) and is present in 
glycolytic tissues, favoring the formation of lactate from pyruvate, while the LDH-1 subunit 
(heart type, also referred to as the B or H subunit) favors the reaction towards the 
production of pyruvate. The different catalytic properties of the five isoenzymes of LDH (H4 
or LDH-1, H3M or LDH-2, H2M2 or LDH-3, HM3 or LDH-4, and M4 or LDH-5) are in 
proportion to the ratio of LDH-5 to LDH-1 subunits. It has been demonstrated that neurons 
contain predominantly LDH-1, while astrocytes express LDH-5 (Bittar et al. 1996). In this 
way, lactate synthesized within astrocytes and released into the interstitial space in brain 
may serve as energy fuel for neurons. Astrocytes release lactate at a greater rate than 
neurons and lactate is preferentially metabolized in neural cells to produce energy and in 
oligodendrocytes to synthesize lipids (to make myelin, Sanchez-Abarca et al., 2001). 
2.2.2 Ketone bodies formation and oxidation  
Glucose is the main energetic fuel for brain. However, under certain conditions the brain can 
meet its energetic needs using ketone bodies. During ketosis, glucose brain consumption 
decreases by about 10% per each mM of plasma ketone bodies (LaManna et al., 2009). 
Ketone bodies are produced from Acetyl-CoA. Lipids are not a major energy source for the 
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brain. Astrocytes are able to oxidize fatty acids and ketone bodies, while neurons and 
oligodendrocytes can only use ketone bodies. 
Ketone bodies are synthesized mainly in the liver. Ketone body synthesis is activated after 
exhaustion of cellular carbohydrate stores (glycogen). Fatty acids are broken down via -
oxidation to Acetyl-CoA, NADH and FADH2. Normally, Acetyl-CoA is completely oxidized 
via the TCA cycle. However, if the amount of Acetyl-CoA generated in fatty-acid -
oxidation increases disproportionately, the processing capacity of the TCA cycle will start to 
drop due to low levels of intermediates. Acetyl-CoA will then be used instead for 
biosynthesis of acetoacetate, -hydroxybutyrate and acetone (ketone bodies) through four 
enzymatic reactions (Figure 4). The utilization of ketones bodies is controlled by leptin 
through AMPK inhibition in the hypothalamic region (Narishima et al., 2011). 
During starvation, during chronic feeding with high fat/low carbohydrate or in 
pathophysiological conditions as diabetes, glucose stores are depleted and ketone body 
synthesis is stimulated. Under these conditions, the concentration of ketone bodies in blood 
increases and MCT expression increases at the blood brain barrier. Within the brain, ketone 
bodies may be used because all brain cells express MCTs and because the enzymatic 
reactions of ketone body synthesis are reversible (except for spontaneous decarboxylation of 
acetoacetate to acetone). Thus brain cells obtain Acetyl-CoA from ketone bodies and Acetyl-
CoA may be oxidized for those cells through the TCA cycle. The starving brain also extracts 
fatty acids from blood. Astrocytes can degrade fatty acids by -oxidation to provide neurons 
with ketone bodies (Edmond, 1992).  Moreover, ketone body oxidation must be important 
during the first postnatal period. Knockout animals for the ketolytic enzyme succinyl-CoA: 
3-oxoacid CoA-transferase exhibit normal prenatal development, but develop ketoacidosis, 
hypoglycemia, and reduced plasma lactate concentrations within the first 48 h of birth 
(Cotter et al., 2011).  
A ketogenic diet has been proposed for treatment of epilepsy. This diet is a strict high fat, 
low protein, low carbohydrate diet, and is anticonvulsant in many drug-resistant epileptic 
children. The diet is also effective in mice. The mechanism by which this diet controls 
intractable seizures is unknown. The diet does not affect behavorial performance or synaptic 
plasticity. Ketone bodies not only function as an energy substrate, but also as intermediates 
for the synthesis of lipids and neurotransmitters. Because of this, a link has been proposed 
between ketone bodies, brain function and polyunsaturated fatty acids (Pifferi et al., 2008). 
Another proposed mechanism to explain the neuroprotective effect of the ketogenic diet is 
via mitochondrial improvement by scavenging of reactive species and regulation of gene 
expression to increase neuronal survival (Beskow et al., 2008). Ketone bodies are also 
proposed as protectors from neurotoxicity in other pathologies, such as Parkinson's disease 
and Alzheimer's disease (Kashiwaya et al., 2000).  
3. Metabolic pathways during brain activation 
The resting brain is not really at rest. It demonstrates continuous cognitive and sensory 
activity. For example, when we listen music, auditive areas of the brain are selectively 
activated. Over 120 years ago, brain activation was shown to produce an increase en blood 
flow in specific brain areas. The increased blood flow has been shown to be accompanied by 
an increase in glucose utilization (Sokoloff et al., 1977). A mechanism that couples neuronal 
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metabolism with blood flow should thus exist. An increase in extracellular K+, adenosine, 
and lactate and related changes in pH are all a consequence of increased neuronal activity. 
All of them have been considered mediators of neurovascular coupling because they have 
vasoactive effects (Villringer & Dirnagl, 1995). Astroglial cells seem to be protagonists in the 
coupling of neuron metabolism and blood flow. Astrocytes, like neurons, are organized into 
networks, although glial cells are organized as a syncytium, linked to each other by gap 
junctions (Giaume et al., 2010). Neuronal cells exchange information through chemical and 
electrical synapses. Astrocyte gap junctions are regulated by extra- and intracelullar signals. 
Astrocytes release molecules that induce local constriction or dilation of smooth muscle cells 
surrounding endothelial cells forming arterioles (Attwell et al., 2010). Astrocytes also release 
molecules in response to neuronal activation. These molecules can modulate synaptic 
transmission and neuronal excitability (a concept referred to as the tripartite synapse, Perea 
& Araque, 2010). So, during brain activation, blood flow is increased due to several 
interactions between brain cells. We will discuss below the metabolic pathways that 
function during brain activation in neuronal and astroglial cells. We will then discuss the 
neuroglial interation and molecular mechanisms that modulate the interaction. 
3.1 Neuron metabolism during activity periods 
In a chemical synapse, neurotransmitters released from the presynaptic neuron bind to 
ionotropic receptors in the postsynaptic membrane increasing the open probability of these 
ion channels. The ion flow can produce membrane depolarization (excitatory action 
potentials) or hyperpolarization (inhibitory action potentials).  Excitatory action potentials 
are produced by the sequential opening of voltage-sensitive Na+ channels, followed by the 
delayed opening of K+ channels. This permits movement of positive charges from and into 
the neuronal cytosol. According to the biophysical properties of neuronal membranes, a 
theoretical minimum positive charge transfer (carried by Na+) was predicted per 
propagating action potential of 121 nC/cm2. This was corroborated by Alle and colleagues 
(2009) who calculated that charging of membrane capacitance requires 153 nC/cm2 only 1.3 
times more than the theoretical minimum. Action potentials are thus energy-efficient, 
minimizing their contribution to activity-dependent metabolism. But human brain has 
billions of neurons and each neuron maintains a large number of synaptic connections to 
other neurons. Even though action potentials are energy-efficient, this is consistent with the 
fact that neuronal activity accounts for 80% of brain energy consumption (Sibson et al., 
1998). Most of the energy consumed in the brain is attributable to restoration of the 
membrane resting potential following depolarization. This is accomplished by the Na+/K+-
ATPase (EC 3.6.1.3, Attwell & Laughlin, 2001). Other energy-consuming processes are 
neurotransmitter recycling and axonal and dendritic transport (Ames, 2000). Because 
glutamate synapses represent at least 80% of cortical synapses, glutamate-mediated 
neurotransmission consumes most of the energy expended in the brain. 
Electrical stimulation opens Na+ channels in neuronal populations. An increase in 
intracellular Na+ concentration activates the Na+/K+-ATPase at its Na+-sensitive 
intracellular site. The activation of Na+/K+-ATPase is accompanied by a decrease in the 
ATP/ADP ratio and glycolysis activation (Figure 6, probably via allosteric activation of 
PFK1 by ADP). Glycolysis activation is accompanied by a Ca2+ increase and an increase in 
pyruvate and NADH/NAD+ concentrations. TCA and oxidative phosphorylation are also 
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stimulated (Figure 6). Indeed, mitochondrial dehydrogenases are activated by an increase in 
intracellular Ca2+ (Figure 4). During glutamatergic activity, glutamate binds to ionotropic 
receptors and metabotropic channels in these cells. Both produce an increase in intracellular 
Ca2+. Glucose oxidation (determined by CO2 production) has been shown to be produced by 
an increased intracellular Na+ concentration in neuronal-enriched cultures. However, 
neuronal cells are unable to stimulate glycolysis via fructose 2,6-bisphosphate (see above, 
Herrero-Mendez et al., 2009). It has thus been proposed that, when energy needs are 
overcome by glycolytic activity stimulated by ADP, neuronal cells preferentially consume 
lactate. Astrocytes release lactate in response to synaptic activation (see below, Magistretti et 
al., 2000) and neuronal cells oxidize this lactate through the TCA and oxidative 
phosphorylation via a mechanism named the neuron lactate shuttle hypothesis (ANLSH, see 
below, Magistretti et al., 1999; Allaman et al., 2010). To facilitate lactate use, glycolysis must 
be inhibited. We will discuss below the details of neuron-glia coupling and the inhibition of 
glucose use. 
The pentose phosphate pathway (PPP) supplies red blood cells with NADPH, which in turn 
maintains the reduced state of glutathione (GSH). GSH has antioxidant properties since the 
thiol group in its cysteine moiety is a reducing agent and can be reversibly oxidized and 
reduced. In cells, GSH is maintained in the reduced form by the enzyme glutathione reductase. 
Regeneration of reduced GSH requires NADPH. Therefore, PPP is important for maintenance 
of adequate levels of GSH (Figure 6). Neurons are thought to be particularly vulnerable to 
damage by reactive oxygen and nitrogen species. Nitrogen species stimulate the PPP rate 
(Bolaños et al., 2010). The brain is a specific source of oxidative species such as those coming 
from metabolism of excitatory amino acids and neurotransmitters. During glutamatergic 
activity, glutamate binds ionotropic receptors and metabotropic channels in these cells. Both 
produce an increase on intracellular Ca2+. The high and constant use of oxygen results in 
oxidative stress through the production of superoxide. Finally, other sources of free radicals 
are produced by Cytochrome P450 and monoamine oxidase activity. It is thus not surprising 
that neuronal cells oxidize glucose through the PPP (Figure 5 and Figure 6), especially, 
considering that neurons are unable to increase glycolysis activity via allosteric activation of 
PFK1 by fructose 2,6-bisphosphate (Figure 1, Herrero-Mendez et al., 2009). 
3.2 Metabolic activation in astrocytes  
Extracellular K+ activates the Na+/K+-ATPase via its extracellular K+-sensitive site in 
cultured astrocytes but not in neurons (Grisar et al. 1979; Hajek et al. 1996).  Na+/K+-ATPase 
activation produces a decrease in the ATP/ADP ratio, and thus glycolysis activation (see 
above, Figure 7, Sokoloff et al., 1996). Extracellular K+ concentrations of between 5 and 12 
mM increase glucose phosphorylation in cultured astrocytes (Hof et al., 1988). The Na+/K+-
ATPase can also be activated by increased intracellular Na+ concentration (Denton et al., 
1988). An increase in intracellular Na+ concentration in astrocytes can be stimulated by the 
presence of glutamate. Glutamate uptake is carried out by excitatory amino acid 
transporters. This transport by excitatory amino acid transporters is dependent on the 
electrochemical gradient of sodium ions. Glutamate uptake can induce metabolic activation 
in astrocytes and can also be used as energetic fuel. Glutamate can be transformed into ┙-
ketoglutarate through a reaction catalyzed by the enzyme aspartate amino transferase (EC 
2.6.1.1, Fonnum, 1967) and thus, glutamate carbons can be oxidized through the TCA. 
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Fig. 5. Relationship between lipid metabolism and the TCA cycle. Under particular dietary 
conditions, such as lactation in newborns or fasting in adults, the ketone bodies acetoacetate 
and -hydroxybutyrate and circulating fatty acids can provide substrates to the TCA cycle 
after their conversion to Acetyl-CoA. Carbon atoms for lipid synthesis can be provided by 
glucose through citrate produced in the TCA cycle, a particularly relevant process for the 
developing brain. 
Glycogen stores may also be mobilized during astrocytic activation (Figure 7). During brain 
activation, neurotransmitters such as noradrenaline can stimulate PTG expression and thus, 
glycogen synthesis (Allaman et al., 2010). However, at the same time, Na+/K+-ATPase 
activation induces a decrease in the ATP/ADP ratio and glycogen catabolism activation. 
Serotonin and other neurotransmitters induce an increase in intracellular concentrations of 
Ca2+ (via IP3 production) and thus, activate glycogenolysis (Chen & Hertz, 1999). Activation 
of glycogen synthesis and degradation is termed the glycogen shunt (Walls et al., 2008). 
Glucose-6-phosphate from glycogen can be oxidized through glycolysis to produce lactate 
which is exported to neurons (Figure 7). It has, in fact, been demonstrated that glycogen is 
required for sustaining glutamatergic neurotransmission and for long-term memory 
formation (Suzuki et al., 2011). 
Besides glutathione, the brain also uses ascorbic acid to protect itself from oxidant species. 
Ascorbic acid is highly concentrated in brain (Kratzing et al. 1982). In aqueous solutions, 
ascorbic acid is a powerful reductant and is oxidized to dehydroascorbic acid. The 
regeneration of ascorbic acid from dehydroascorbic acid is not spontaneous. Reduction is 
mainly an enzymatically catalyzed reaction, which may be glutathione-dependent (Ishikawa 
et al. 1998). Astrocytes are thought to be involved in ascorbic acid recycling (Figure 10, 
Astuya et al. 2005). During synaptic activity, ascorbic acid is released from intracellular 
reservoirs (O’Neill et al. ,1984; Ghasemzadeh et al., 1991; Yusa, 2001). The molecular basis of 
ascorbic acid efflux is not yet well known. Neurons can take up ascorbic acid efficiently 
because they express SVCT2 (Castro et al., 2001). Ascorbic acid is oxidized within neurons  
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Fig. 6. Neuron metabolism during synaptic activity. Electrical stimulation opens Na+ 
channels in neuronal cells. An increase in intracellular Na+ concentration is able to activate 
Na+K+--ATPase at its Na+-sensitive intracellular site (early phase). This activation produces a 
decrease in ATP/ADP ratio and thus, glycolysis activation by allosteric activation of PFK1 
by ADP. Glycolysis activation is accompanied by Ca2+ increase and therefore, mitochondrial 
oxidative metabolism activation. In the late phase of synaptic activation, glycolysis activity 
is inhibited and lactate uptake is stimulated (see Figure 10 for details of inhibition of glucose 
utilization and stimulation of lactate transport in synaptically-active neurons). PPP is always 
present in neuronal cells because NADPH is required to maintain the redox balance in these 
cells. During synaptic activity, PPP becomes more important because synaptic activity 
produces oxidant species. NADPH is used to regenerate GSH and thus, to reduce oxidant 
species.  
because during synaptic activity many oxidant species are generated. Neuronal oxidized 
ascorbic acid (dehydroascorbic acid) can be released through glucose transporters, GLUT1 
or GLUT3 (because dehydroascorbic acid is a substrate for GLUTs; Vera et al., 1993). 
Astrocytes uptake dehydroascorbic acid through GLUT1 and thus, they reduce 
dehydroascorbic acid to ascorbic acid through mechanisms that require GSH. GSH 
regeneration and PPP activation under synaptic transmission conditions should thus be 
important for astrocytes (Figure 7, Figure 10). 
Astrocytic cells also express metabotropic glutamate receptors (mGluRs). Thus, during 
excitatory brain activation, glutamate is not only taken up by excitatory amino acid 
transporters, but glutamate activates mGluRs, which produce and increase intracellular Ca2+ 
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and the production of arachidonic acid and prostaglandins. These substances stimulate 
dilation or constriction of adjacent arterioles and permit that the correct nutrients and 
oxygen supply are present in order to sustain neurotransmission (Peppiat & Attwell, 2004).  
3.3 Neuron-glia metabolic coupling 
As we discuss above, the key to neuron-glia metabolic coupling is the excitatory 
neurotransmitter glutamate and a rise in extracellular K+. Glutamatergic synaptic activity is 
necessary to maintain a low glutamate concentration in the extracellular space for efficient 
and successful synaptic transmission to occur and to prevent excitotoxicity. Glutamate 
uptake in astrocytes occurs via excitatory amino acid transporters. Within the cell, glutamate 
is then converted to glutamine by glutamine synthetase (EC 6.3.1.2). Glutamine is released 
into the extracellular space and is taken up by adjacent neurons that synthesize glutamate 
from glutamine in a reaction catalyzed by glutaminase (EC 3.5.1.2). This recycling of 
glutamate is named the glutamate–glutamine cycle (Figure 10, Sibson et al., 1997).  
 
Fig. 7. Metabolic activation of astrocytes. Synaptic activity produces an increase in 
extracellular K+, which stimulates Na+K+-ATPase by binding of its extracellular K+-sensitive 
site.  The excitatory neurotransmitter glutamate is taken up by astrocytes through excitatory 
amino acid transporters. This kind of transport produces an increase in intracellular Na+, 
which stimulates Na+K+-ATPase by binding of its intracellular Na+-sensitive site. Na+K+-
ATPase activation produces a decrease in ATP/ADP ratio and, thus glycolysis and 
glycogenolysis activation. In addition, glucose is oxidized by PPP to produce NADPH and 
to maintain the redox balance, reducing glutathione and ascorbic acid (Asc). Ascorbic acid 
released by astrocytes is taken up by neurons to protect themselves from oxidant species 
(ascorbic acid is oxidized in neurons). Oxidized ascorbic acid (dehydroascorbic acid, Asc+) is 
released from neurons and taken up by astrocytes through GLUT1. Finally, in astrocytes, 
glutamate is able to bind ionotropic receptors, which are predominantly calcium channels. 
This Ca2+ increase cooperates with TCA activation and produces arachidonic acid (AA) and 
prostaglandin (PG) which stimulate the constriction and dilation of capillaries, respectively.  
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According to ANLSH, glutamate uptake also stimulates glucose uptake (Pellerin & 
Magistretti, 1994), glycolysis and lactate release in astrocytes (Pellerin & Magistretti, 1994; 
Demestre et al., 1997). In a similar way, glycolysis and glucose uptake is activated by an 
increase in the extracellular concentration of K+ (Pellerin & Magistretti, 1994; Gegelashvili et 
al., 2007). An increased extracellular K+ concentration stimulates 2-deoxyglucose 
phosphorylation (Hof et al., 1988) and lactate formation and release of lactate (Walz & 
Mukerji, 1988) in cultured astrocytes. Neurons take up the lactate released from astrocytes 
(Figure 10, Magistretti et al., 2000; Allaman et al., 2010). Lactate flow happens would be 
possible because there are a differential MCTs and LDH isoenzymes expression between 
neuronal and astroglial cells. However, use of neuronal lactate has been strongly debated in 
studies that support the idea that glucose is the main metabolic substrate for these cells 
(Chih & Roberts, 2003; Dienel, 2009; Gjedde, 2002; Hertz, 2004; Hertz et al., 2007; Mangia et 
al., 2003; Mangia et al., 2009).  
Activation of glycolysis produces an increase in pyruvate and proton concentrations that are 
accompanied by a decrease in the NAD+/NADH ratio. Neuronal LDH1 should catalyze 
reduction of pyruvate to lactate. So, lactate utilization by neurons would only be possible if the 
consumption of glucose, either at the transport or the glycolysis stage, were inhibited. To 
explain this, at least four different (though coexistent) ideas have been proposed (Figure 10). 
Firstly, using real-time microscopy, glucose transport inhibition by glutamate has been 
demonstrated in neurons co-cultured with astrocytes (Porras et al., 2008). But because these 
experiments were performed with co-cultures, it is not possible to discard the possibility that 
astrocytic stimulation by glutamate may induce the release of substances which inhibit glucose 
uptake in neurons. In other words, it is possible that the effect of glutamate on neuronal 
glucose uptake may be indirect. The second mechanism is explained by the redox 
switch/redox coupling hypothesis (Cerdan et al., 2006). This idea embraces a mechanism in 
which two different pyruvate pools exist: one is thought to operate in exchange with 
extracellular lactate or pyruvate and the other, thought to be derived from glycolytic activity. 
This mechanism considers a lactate/pyruvate redox shuttle, which is able to transfer lactate 
from astrocytes to neurons. So, high cytosolic lactate inhibits neuronal glycolysis at the 
glyceraldehyde- 3-phosphate dehydrogenase (EC 1.2.1.12) step by competing with cytosolic 
NAD+, favoring oxidation of extracellular lactate. The third mechanism is our own theory. We 
have demonstrated that neuronal intracellular ascorbic acid inhibits glucose utilization in 
neurons (Castro et al., 2009) through GLUT3 inhibition (Figure 8, Beltrán et al., 2011). This 
mechanism is supported by the idea of ascorbic acid recycling in brain (see above, Figure 10, 
Astuya et al., 2005). Using primary cultures of cortical neurons treated with a specific shRNA 
(to block GLUT3 expression) and a fluorescent glucose analogue, we have shown that this 
transporter is important, using real-time experiments (Figure 7). At the same time, intracellular 
ascorbic acid is able to stimulate lactate transport in neurons and in cells that express GLUT3 
(Figure 9, Castro et al., 2008). Because ascorbic acid is able to change metabolic substrate 
preferences, we have termed this mechanism the ascorbic acid metabolic switch (Castro et al., 
2009). The fourth proposed mechanism relates to the inability of neuronal cells to overactivate 
glycolysis (Herrero-Mendez et al., 2009; Bolaños et al., 2010). This idea is supported by elegant 
experimental data that demonstrate that in neurons, it is not possible to produce the allosteric 
activator of PFK1 (and therefore glycolysis activator) fructose 2,6-bisphosphate. The enzyme 
that catalyzes fructose-2,6-bisphosphate in neurons, PFK3B, has a very short half-life as it is 
being constantly degraded (Herrero-Mendez et al., 2009). This mechanism does not exclude 
basal glycolytic activity however. 
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Fig. 8. Intracellular ascorbic acid only inhibits transport of 2-NBDG in cells expressing 
GLUT3. A: Time course of uptake of 2-NBDG (2-[N-(7-nitrobenz-2-oxa-1,3-diazol-4-
yl)amino]-2-deoxyglucose). 2-NBDG transport in cortical neurons in the presence (closed 
circles) or absence (open circles) of intracellular ascorbic acid. B: Time course of uptake of 2-
NBDG transport in neuronal cells treated with shRNA to knock down GLUT3 expression in 
the presence (triangles) or absence (circles) of intracellular ascorbic acid. The data represent 
the mean ± SD of four experiments (14 control cells and 10 shRNA-treated cells). The images 
represent one control experiment and one experiment with shRNA-treated cells, in the 
presence or absence of ascorbic acid. Adapted from Beltran et al. (2011) with permission of 
the publisher. 
4. Metabolic failure in neurodegenerative diseases 
Neurodegenerative disease is a broad term for a range of conditions which primarily affect 
neurons in the brain. Progression of neurodegenerative diseases is accompanied by loss of 
neuronal cell structure and function and even cell death. These diseases have many 
similarities at a sub-cellular level including atypical protein assemblies, failure of normal 
protein degradation pathways, induced cell death, impaired axonal transport and metabolic 
failures (Rubinsztein et al., 2006; De Vos et al., 2008; Bredesen et al., 2006; Lin & Beal, 2006). 
A better knowledge of how these failures arise may offer fresh hope for development of 
therapies that improve treatment of these diseases.  
Directly or indirectly, energy is necessary for many, if not all, cellular processes. It is thus 
possible to speculate that metabolic failure is an early event in neurodegenerative disease. 
Indeed, there are neurodegenerative diseases caused by a deficiency of metabolic enzymes. 
One of these is pyruvate dehydrogenase complex deficiency (Brown et al., 1994). This 
condition has similar characteristics to those of other neurodegenerative diseases. Several 
neurodegenerative disorders, such as Alzheimer's disease, Huntington's disease and 
Parkinson's disease, show metabolic failure represented by altered patterns of expression of 
nutrient transporters, metabolic enzymes and molecular components of cellular respiration. 
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Fig. 9. Intracellular ascorbic acid stimulates lactate uptake in cells expressing GLUT3. 
Substrate dependence for the inhibition of 0.1 mM lactate transport (10 s, 20 oC) by 
intracellular ascorbic acid (cells were preloaded with ascorbic acid at the concentrations 
indicated) in cultured cortical astrocytes (gray bars) and cultured cortical astrocytes 
expressing GLUT3-EGFP (black bars). Cortical astrocytes were transfected through 
electroporation. The data represent the mean ± SD of three experiments.  
Metabolic failure is also represented by altered activities of the enzymes involved in energy 
metabolism. Mitochondria are the main platform for oxidative metabolism. They participate 
in cell metabolism, they produce ATP and they are important regulators of cytosolic 
calcium, which in turn, is related to whether or not programmed cell death occurs. 
Neurodegenerative diseases trigger programmed cell death and thus the role of 
mitochondria is key, from beginning to end of the disease, from the initial failure in energy 
metabolism to the later onset of cell death. 
4.1 Alzheimer's disease 
Alzheimer's disease is the most common cause of dementia. It is characterized by 
progressive cognitive dysfunction. The Alzheimer's disease brain appears atrophied. The 
temporal lobe, parietal lobe, frontal cortex and cingulate gyrus show degeneration and loss 
of cellular mass (Wenk, 2003).  Parkinson's disease is characterized by loss of neurons and 
synapses in the cerebral cortex and in some subcortical regions. Genetically, Alzheimer's 
disease is heterogeneous and complex, showing no simple mode of inheritance. The causes 
of most Alzheimer's disease cases are still unknown, though in 1-5% of cases, genetic 
differences have been described. There are two neuropathological changes that can be 
correlated with an Alzheimer's disease diagnosis. First of all, neurofibrillary tangles (NFTs) 
accumulate in neuronal cytosol. And secondly, extracellular amyloid deposits appear in the 
form of senile plaques containing amyloid peptide (Duyckaerts et al., 2008).  
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Fig. 10. Neuron-glia metabolic coupling. During glutamatergic synaptic activity, increases in 
extracellular glutamate and K+ concentration are produced. This metabolically activates 
these cells (see Figure 7 for details of astrocytic metabolic activation). Astrocytes uptake 
glutamate and convert it into glutamine. Glutamine is released and taken up by neuronal 
cells to glutamate resynthesis (glutamate-glutamine shuttle). Metabolic activation of 
astrocytes produces an increase in glycolysis, glycogenolysis activities and lactate 
production. Lactate is taken up by neurons to support their energetic needs (astrocyte-
neuron lactate shuttle). Lactate uptake and lactate oxidation in neurons is possible because 
these cells are not able to activate glycolysis through fructose 2,6-bisphosphate production 
(see Figure 6 for details of metabolism in synaptically-active neuronal cells). Glutamate also 
stimulates ascorbic acid release form astrocytes. Neuronal cells take up ascorbic acid 
through SVCT2. Intracellular ascorbic acid inhibits glucose transport through GLUT3 
inhibition and stimulates lactate transport (ascorbic acid metabolic switch). Synaptic activity 
is accompanied by production of oxidant species. Thus ascorbic acid is oxidized to reduce 
that species. Dehydroascorbic acid (oxidized ascorbic acid, Asc+) is released by neurons and 
taken up by astrocytes through GLUT1. Astrocytes reduce dehydroascorbic acid to ascorbic 
acid via gluthathione-dependent reductases (ascorbic acid recycling). Glu: glutathione, Gluc: 
glucose, Gln: glutamine, Lac: lactate, Pyr: pyruvate. 
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Type 2 diabetes mellitus appears to be a significant risk factor for Alzheimer's disease (Bosco 
et al., 2011). Alzheimer's disease is characterized by a significant and pre-symptomatic 
reduction of brain glucose utilization (Table 1, Ferreira et al., 2010). Indeed, it has been 
proposed that early diagnosis of Alzheimer's disease will be rendered possible through a 
combination of imaging modalities (such as magnetic resonance imaging, MRI and positron 
emission tomography, PET; Mosconi et al., 2005). There is a correlation between impairment of 
glucose cerebral metabolism, decreased GLUT expression and cerebral spinal fluid tau 
protein levels. (Liu et al., 2008; Cevarolo et al., 2008). Indeed, patients show decreased 
GLUT3 levels (Liu et al., 2008, Harr et al., 1995). A decrease in glycolytic enzyme levels and 
activity, PFK1 and glyceraldehyde-3-phosphate dehydrogenase (EC 1.2.1.12) has also been 
described. Decreased glycolysis could be related to an increase in glycogen synthesis. 
Pharmacological glycogen synthase kinase 3 inhibition improves behavioral dysfunction 
and decreases tau phosphorylation (Onishi et al., 2011). A spatial correlation between brain 
glycolysis without oxidative mitochondrial metabolism and amyloid deposition has been 
described (Vlassenko et al., 2010). Aggregate forms of amyloid can modify glucose 
metabolism and oxidative stress in astrocytes, affecting neuronal cells and probably 
contributing to neuronal death (Allaman et al., 2010). Indeed, reduction of GLUT1 and MCT 
expression, as well as the retraction of of astrocyte endfeet occurs in Alzheimer's disease 
producing uncoupling of the neurovascular unit (Merlini et al., 2011). The activity of PPP is 
increased in Alzheimer's disease. Increased oxidative stress markers in Alzheimer's disease 
samples correlated with enhanced PPP activity suggesting that PPP activity could play a 
role in the response against brain pro-oxidant activity in Alzheimer's disease. Finally, 
mitochondrial dysfunction (Schapira et al., 2006), decreased expression of oxidative 
phosphorylation and reduced activity of cytochrome oxidase were all observed in 
Alzheimer's disease. 
4.2 Huntington's disease 
Huntington's disease is a progressive, autosomal dominant, neurodegenerative disorder. It 
can affect individuals of all ages, from infancy to old age and develops over a period of 15-
20 years. Motor dysfunction and cognitive abnormalities are common symptoms. The 
disease is caused by an expanded polyglutamine (polyQ) stretch in the corresponding 
causal gene. Huntington's disease represents one of a growing number of polyQ repeat 
diseases that cause region-specific neuronal degeneration, including spinobulbar muscular 
atrophy and spinocerebellar ataxias (Pennuto et al., 2009). In Huntington's disease, polyQ 
expansion affects the Huntingtin gene, resulting in major cell loss in the striatum, a region of 
the basal ganglia that integrates cortical information for behavioral output. Huntington's 
disease is characterized by widespread neurodegeneration with preferential deterioration of 
medium-sized spiny neurons (MSSNs) in the striatum (Penney & Young, 1998). The major 
excitatory input to MSSNs comes from the cortex (corticostriatal pathway) and the 
thalamus. Huntington's disease also causes dysfunction and subsequent death of neurons in 
other brain regions, including the cortex.  
The Huntingtin gene codes for a protein called the huntingtin protein (Htt). It is a soluble 384 
kDa protein, essential for embriogenesis, and ubiquitously expressed in moderate amounts 
in the nervous system as well as in other systems (Cattaneo et al., 2001). Htt is associated 
with various intracellular organelles, including the nucleus, endoplasmic reticulum, Golgi 
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complex, microtubules and endosomal compartments. Wild-type (normal) huntingtin has 
an important role in the intracellular transport of vesicles, organelles and traffic of proteins 
to the cell surface (Caviston et al., 2009). Expansion of a glutamine stretch within the Htt 
protein to more than 40 repeats appears to confer a dominant toxic property that is 
deleterious to neurons and detrimental to normal Htt biological activities. The precise 
actions of the mutant huntingtin are still not clearly understood. 
Huntington's disease is characterized by a failure in brain energy metabolism (Table 1). Defects 
in energy metabolism may even extend to presymptomatic subjects. Positron emission 
tomography studies have demonstrated marked reductions in glucose metabolism in the basal 
ganglia (Mazziotta et al., 1987), and in the cerebral cortex of symptomatic Huntington's disease 
patients (Leenders et al., 1986; Kuwert et al., 1993). However, Oláh and colleagues (2008) 
described an increase in several glycolytic enzymes and ATP production in brain from 
Huntington's disease animals. By contrast, the same authors described a marked decrease in 
glyceraldehyde-3-phosphate dehydrogenase activity. An impairment in enzyme activity of the 
TCA cycle (Lim et al., 2008) and oxidative phosphorylation has also been described. A key role 
for proliferator-activated receptor gamma coactivator-1  has been proposed in the control of 
energy metabolism in the early stages of Huntington's disease pathogenesis. Proliferator-
activated receptor gamma coactivator-1  is a transcriptional coactivator that regulates several 
metabolic processes, including mitochondrial biogenesis and oxidative phosphorylation (Finck 
& Kelly, 2006). Although the origin of metabolic impairment is unknown, it is proposed that a 
systematic downregulation of persoxisome proliferator-activated receptor- plays a critical role 
in the deregulation of energy homeostasis observed in Huntington's disease (Chiang et al., 
2010). Metabolic failure in Huntington's disease not only occurs in brain. Htt is a ubiquitous 
protein and thus energetic failure may also be observed in peripheral tissues. Huntington's 
disease patients do show progressive weight loss and development of diabetes (Aziz et al., 
2010). These symptoms may be related to an impairment of insulin secretion (Smith et al., 
2009). 
Finally, oxidative damage has been shown (Mazziotta et al., 1987), as well as impaired SOD 
activity (Mazziotta et al., 1987) and impaired ascorbic acid homeostasis (Rebec et al., 1994) in 
Huntington's disease animal models. Our group has been making steady progress with 
respect to the function of ascorbic acid in neuronal metabolism (Castro et al., 2008; Castro et 
al., 2009; Beltrán et al., 2011, see above). Ascorbic acid, the reduced form of vitamin C, 
modulates neuronal metabolism between resting state and brain activation periods.  
4.3 Parkinson's disease 
Parkinson's disease is the most common neurodegenerative movement disorder of central 
nervous system. Clinical symptoms are due to the progressive degeneration of 
dopaminergic neurons in the substantia nigra and other monoaminergic neurons in the 
brainstem (Braak et al., 2003). The pathology of this disease is characterized by the 
accumulation of -synuclein into inclusions called Lewy bodies in neurons. Although 
Parkinson's disease is a sporadic condition of uncertain ethiology, there is some evidence 
that mitochondrial dysfunction considerably contributes to the pathogenesis of this disorder 
(Schapira, 2008). Mutations in several genes are found in Parkinson's disease. Point 
mutations, duplications and triplications in the -synuclein gene and mutations in the 
leucine-rich repeat kinase 2 (LRRK2). Mutations have also been described in genes coding  
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CNS DISEASE METABOLIC FAILURE REFERENCES 
Alzheimer’s  
Disease (AD) 
Reduced glucose metabolism in AD patients and 
animal models via measurement of CMRgl by 
FDG-PET. Early hypometabolism in posterior 
associative cortical areas and prefrontal areas. 
Increased activity of G6PDH in temporal cortex of 
AD patients. Increased G6PDH levels in pyramidal
neurons from hippocampus. Mitochondrial 
dysfunction including: mtDNA mutation, 
decreased mRNA levels for complex I-IV subunits 
of the electron transport chain. Decreased activities
of glycolytic enzymes, lower pyruvate synthesis, 
lower pyruvate dehydrogenase activity, lower 
Acetyl-CoA production and impaired 
cycloxygenase activity. Decreased expression of 
GLUT1 and MCT1 in blood brain barrier of AD 
animal models, decreased GLUT1 and GLUT3 in 
AD brains. Decreased amount of GLUT-1 
transporter in the hippocampus and cerebral 
cortex of AD patients. 
Browen et al., 1979 
Ferreira et al., 2010; Harr et 
al., 1995; Hooijimans et al., 
2007; Horwood & Davies, 
1994; Kalaria & Harik,1989;; 
Langbaum et al., 2009; Liu 
et al., 2008; Merlini et al., 
2011;  Mooradian et al., 
1997;; Nicholson et al., 2010; 
Ojaimi et al., 1999; Parker et 
al., 1994; Schapira et al., 
2006; Shima et al., 2011; 
Simpson et al., 1994; Sims et 
al., 1983; Sorbi et al., 1983; 
Villain, 2010. 
Huntington’s 
disease (HD) 
Reduced glucose metabolism in the basal ganglia 
and cerebral cortex of symptomatic HD patients. 
Deficiency in activities of respiratory chain 
complexes II, III and IV in caudate nucleus. 
Decreased cAMP levels in HD postmortem brain 
and HdhQ111 striatum. Decreased ATP and 
ATP/ADP ratio. Defective mitochondrial 
oxidative phosphorylation. Cytochrome oxidase 
subunit I (COI) mRNA levels are reduced within 
neurons of the putamen and globus pallidus. 
Expression of mHTT in hypothalamus causes 
metabolic imbalance in mice. Decreased GLUT1 
and GLUT3 transporter expression in caudate of 
postmortem HD brains. 
Gamberino & Brennan, 
1994;  
Gourfinkel-An et al., 2002;  
Gu et al., 1996; Hult et al., 
2011;  Kuwert et al., 1990; 
Kuwert et al., 1993; 
Leenders et al., 1986; Lim et 
al., 2007; Mann et al., 1990; 
Martin et al., 1992; 
Mazziotta et al., 1987;  
Parkinson’s 
disease (PD) 
Hypometabolism in striatal, thalamic, and motor 
regions in PD animal models with significant 
alterations in striatal and cortical function (FDG-
PET). PD patients showed patterns of decreased 
metabolism in bilateral inferior, medial frontal and
right parietal lobes, caudate nucleus and visual 
cortex. Deficiency in the activity of complex I in 
mitochondria of  substantia nigra. Glucose 
metabolism is decreased in the caudate, putamen 
and thalamus in a primate PD model.  
Bohnen et al., 2011; 
Borghammer et al., 2011 
Brownell et al., 2003; Feng 
et al., 2008; Hattingen et al., 
2009; Hou et al., 2010; Hyu 
Lee et al., 2009; Lee et al., 
2010; Lyoo et al., 2008; 
Perneczky et al., 2008; 
Schapira et al., 1989. 
 
Table 1. Metabolic failures in neurodegenerative diseases. 
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for Parkin, DJ-1, PINK1 and ATP13A2 (Biskup et al., 2008). The exact role of -synuclein 
remains unknown, but it is thought to participate in maintenance of vesicle pools. Parkin 
directs ubiquitination of -synuclein (Haywood & Staveley, 2004). Ubiquitin tagged -
synuclein is directed to proteosome and degraded. The parkin protein thus promotes 
Parkinson's disease by enhancing the failure in normal protein degradation. Mutations in 
PINK1 and DJ1 genes are related to mitochondrial dysfunction in Parkinson's disease. 
Oxidative stress also occurs in Parkinson's disease. Dopamine metabolism produces oxidant 
species. In this way, the -synuclein mutation contributes to oxidative stress because in the 
presence of mutated -synuclein, dopamine remains in the cytosol instead of being loaded 
into synaptic vesicles (Henchcliffe, 2008). 
A hypometabolism of glucose has been described in Parkinson's disease patients (Huang et 
al., 2007; Yong et al., 2007; Perneczy et al., 2008; Hosokai et al., 2009; Lee et al., 2008; Lee et 
al., 2010; Bohnen et al., 2011; Borghammer et al., 2011). However, there is only limited 
molecular evidence to support this feature. Defects in oxidative phophorylation with a 
decreased activity of complex I have been reported (Navarro et al., 2009; Hattingen et al., 
2009). This evidence leads us to speculate that in Parkinson's disease, mitochondrial 
dysfunction by redox imbalance precedes metabolic failure. However, a role for glycogen 
synthase kinase 3-3, an enzyme participating in glycogen metabolism (see below) has been 
proposed in Parkinson's disease pathogenesis (as for Alzheimer's disease pathogenesis, 
Nagao et al., 2008; Garcia-Gorotiaga et al., 2009). 
5. Conclusions 
The metabolic cost of brain activity is high. Neuronal activity accounts for 80% of brain 
energy consumption. Glucose is an essential energy source for the adult human brain. It can 
be used to obtain energy and to produce metabolic intermediaries for biosynthesis of 
compound of biological interest. Glucose can also be stored in brain, in the form of 
glycogen. Glucose oxidation via glycolysis occurs in all brain cells. However, the ability of 
neuronal cells to activate this metabolic pathway is poor. Astrocytic glycolysis and 
glycogenolysis is activated in response to synaptic activation with the subsequent formation 
of lactate.  Thus, during glutamatergic synaptic activity neurons preferably consume lactate 
released from glia. The energetic coupling between neuronal and astroglial cells is essential 
to meet energy brain needs in an efficient way. Astrocytes interact with each other and with 
endothelial cells from the blood brain barrier and smooth muscle cells surrounding 
arterioles. Under fasting conditions, during intense exercise and in suckling infants, ketone 
bodies are a significant source of energetic fuel for brain. Metabolic failure has been 
described in several neurodegenerative diseases. These diseases present atypical protein 
assemblies, failures in normal protein degradation pathways, induced cell death, impaired 
axonal transport and metabolic failures. Almost all cellular processes need energy. It is thus 
possible that metabolic failure is an early event in these pathologies. This hypothesis is 
supported by evidence that shows metabolic failure in pre-symptomatic patients suffering 
from diseases such as Alzheimer's disease and Huntington's disease. 
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